Hikma to launch colchicine in USA as Takeda’s injunction fails
Jordon-headquartered Hikma Pharmaceuticals (LSE: HIK) saw its shares rise 4.2% to a record high of £23.80, after a USA appeals court rejected Japanese drug major Takeda Pharmaceutical’s (TY0: 4502) bid to bock the firm’s launching of its gout drug colchicine.
Hikma will now prepare to distribute its colchicine 0.6mg capsules, which it will market under the brand name Mitigare. Hikma says it will also be preparing to launch an authorized generic of Mitigare, increasing patient access to this important product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze